Hims & Hers Health (HIMS) Stock Forecast & Price Target

Compare

6,418 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIMS Analyst Ratings

Hold

1 Buy

8 Hold

2 Sell

Based on 11 analysts giving stock ratings to

Hims

& Hers Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$39.80

▼(-16.14%Downside)

Based on 11 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $39.80 with a high forecast of $68.00 and a low forecast of $25.00. The average price target represents a -16.14% change from the last price of $47.46.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","27":"$27","41":"$41","55":"$55","69":"$69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,27,41,55,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.77,57.63384615384616,58.49769230769231,59.361538461538466,60.22538461538462,61.089230769230774,61.95307692307692,62.816923076923075,63.68076923076923,64.54461538461538,65.40846153846154,66.27230769230769,67.13615384615385,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.77,55.464615384615385,54.159230769230774,52.853846153846156,51.54846153846154,50.24307692307693,48.93769230769231,47.63230769230769,46.32692307692308,45.02153846153846,43.716153846153844,42.41076923076923,41.105384615384615,{"y":39.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.77,54.32615384615385,51.88230769230769,49.43846153846154,46.994615384615386,44.550769230769234,42.10692307692308,39.66307692307692,37.21923076923077,34.77538461538462,32.33153846153846,29.887692307692305,27.443846153846152,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.42,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.85,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.09,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":31.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.16,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.77,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$39.80

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$53

Buy

11.67%

Upside

Reiterated

07/03/25

Hims & Hers Health's robust financial performance and positive earnings call sentiment are the primary strengths, showcasing strong growth and strategic direction. However, the high valuation and mixed technical signals highlight potential risks, balancing the overall positive outlook.

Craig HettenbachMorgan Stanley

Morgan Stanley

$40

Hold

-15.72%

Downside

Reiterated

06/30/25

Legal Challenges and Uncertainty Justify Hold Rating on Hims & Hers Health

George HillDeutsche Bank

Deutsche Bank

$43

Hold

-9.40%

Downside

Reiterated

06/24/25

Hims & Hers Health (HIMS) Gets a Hold from Deutsche Bank

Michael ChernyLeerink Partners

Leerink Partners

$42

Hold

-11.50%

Downside

Reiterated

06/24/25

Hims & Hers Health (HIMS) Gets a Hold from Leerink Partners

Maria RippsCanaccord Genuity

Canaccord Genuity

$68

Buy

43.28%

Upside

Reiterated

06/23/25

Hims & Hers Health: Strong Growth Potential Despite Novo Nordisk Partnership Termination

Ryan MacDonaldNeedham

Needham

―

Hold

―

Downgraded

06/23/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)

Allen LutzBank of America Securities

Bank of America Securities

$28

Sell

-41.00%

Downside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Jailendra SinghTruist Financial

Truist Financial

$45

Hold

-5.18%

Downside

Reiterated

06/23/25

Truist Financial Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Daniel GrosslightCiti

Citi

$64.22→$30

Sell

-36.79%

Downside

Reiterated

06/20/25

Hims & Hers Health (HIMS) Receives a Sell from CitiWe think we may see Novo take similar legal action to LLY accusing virtual health providers of engaging in the corporate practice of medicine (prohibited in many states) by unduly influencing their affiliated provider groups to switch patients from commercially available dosages to “personalized dosages” of GLP-1s post-shortage. Additionally, when the partnership was first announced, it seemed to indicate Novo would be collaborating with HIMS on future indications. Unless HIMS changes its compounded semaglutide prescribing practices, this is exceedingly unlikely now, in our view.

Jonna KimTD Cowen

TD Cowen

$38

Hold

-19.93%

Downside

Reiterated

06/03/25

Hims & Hers Health (HIMS) Gets a Hold from TD Cowen

Korinne WolfmeyerPiper Sandler

Piper Sandler

$35→$39

Hold

-17.83%

Downside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Glen SantangeloJefferies

Jefferies

$21→$25

Hold

-47.32%

Downside

Reiterated

04/11/25

Hims & Hers price target raised to $25 from $21 at JefferiesHims & Hers price target raised to $25 from $21 at Jefferies

Aaron KesslerSeaport Global

Seaport Global

$55

Buy

15.89%

Upside

Reiterated

03/01/25

Eric PercherBarclays

Barclays

$40

Hold

-15.72%

Downside

Downgraded

02/25/25

Nephron downgrades Hims and Hers (HIMS) to HoldNephron analyst Eric Percher downgraded Hims and Hers (NYSE: HIMS) from Buy to Hold with a price target of $40.00.

David LarsenBTIG

BTIG

$85

Buy

79.10%

Upside

Reiterated

02/24/25

BTIG Sticks to Their Buy Rating for Hims & Hers Health (HIMS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$53

Buy

11.67%

Upside

Reiterated

07/03/25

Craig HettenbachMorgan Stanley

Morgan Stanley

$40

Hold

-15.72%

Downside

Reiterated

06/30/25

Legal Challenges and Uncertainty Justify Hold Rating on Hims & Hers Health

George HillDeutsche Bank

Deutsche Bank

$43

Hold

-9.40%

Downside

Reiterated

06/24/25

Hims & Hers Health (HIMS) Gets a Hold from Deutsche Bank

Michael ChernyLeerink Partners

Leerink Partners

$42

Hold

-11.50%

Downside

Reiterated

06/24/25

Hims & Hers Health (HIMS) Gets a Hold from Leerink Partners

Maria RippsCanaccord Genuity

Canaccord Genuity

$68

Buy

43.28%

Upside

Reiterated

06/23/25

Hims & Hers Health: Strong Growth Potential Despite Novo Nordisk Partnership Termination

Ryan MacDonaldNeedham

Needham

―

Hold

―

Downgraded

06/23/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)

Allen LutzBank of America Securities

Bank of America Securities

$28

Sell

-41.00%

Downside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Jailendra SinghTruist Financial

Truist Financial

$45

Hold

-5.18%

Downside

Reiterated

06/23/25

Truist Financial Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Daniel GrosslightCiti

Citi

$64.22→$30

Sell

-36.79%

Downside

Reiterated

06/20/25

Jonna KimTD Cowen

TD Cowen

$38

Hold

-19.93%

Downside

Reiterated

06/03/25

Hims & Hers Health (HIMS) Gets a Hold from TD Cowen

Korinne WolfmeyerPiper Sandler

Piper Sandler

$35→$39

Hold

-17.83%

Downside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Glen SantangeloJefferies

Jefferies

$21→$25

Hold

-47.32%

Downside

Reiterated

04/11/25

Hims & Hers price target raised to $25 from $21 at JefferiesHims & Hers price target raised to $25 from $21 at Jefferies

Aaron KesslerSeaport Global

Seaport Global

$55

Buy

15.89%

Upside

Reiterated

03/01/25

Eric PercherBarclays

Barclays

$40

Hold

-15.72%

Downside

Downgraded

02/25/25

Nephron downgrades Hims and Hers (HIMS) to HoldNephron analyst Eric Percher downgraded Hims and Hers (NYSE: HIMS) from Buy to Hold with a price target of $40.00.

David LarsenBTIG

BTIG

$85

Buy

79.10%

Upside

Reiterated

02/24/25

BTIG Sticks to Their Buy Rating for Hims & Hers Health (HIMS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

1 Month

xxx

Success Rate

9/17 ratings generated profit

Average Return

+0.21%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +0.21% per trade.

3 Months

xxx

Success Rate

12/19 ratings generated profit

Average Return

-1.16%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of -1.16% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

13/19 ratings generated profit

Average Return

+18.24%

reiterated a sell rating 12 days ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +18.24% per trade.

2 Years

xxx

Success Rate

13/19 ratings generated profit

Average Return

+25.54%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +25.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIMS has received 5 Buy Ratings, 30 Hold Ratings, and 17 Sell Ratings. HIMS average Analyst price target in the past 3 months is 39.80.

Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is $0.15 with a range of $0.05 to $0.26. The previous quarter’s EPS was $0.20. HIMS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year HIMS has Preformed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $549.87M with a range of $540.01M to $564.00M. The previous quarter’s sales results were $586.01M. HIMS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year HIMS has Preformed in-line its overall industry.

HIMS Stock Forecast FAQ

What is HIMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 39.80.

What is HIMS’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HIMS, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HIMS a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Hold which is based on 1 buy ratings, 8 hold ratings and 2 sell ratings.

What is Hims & Hers Health’s price target?

The average price target for Hims & Hers Health is 39.80. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $25.00. The average price target represents -16.14% Decrease from the current price of $47.46.

What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of HIMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Hims & Hers Health (HIMS) Stock Forecast & Price Target

HIMS Analyst Ratings

HIMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hims & Hers Health

HIMS Analyst Recommendation Trends

HIMS Financial Forecast

HIMS Earnings Forecast

HIMS Sales Forecast

HIMS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts